Literature DB >> 20622893

BRCA1-IRIS overexpression abrogates UV-induced p38MAPK/p53 and promotes proliferation of damaged cells.

K Chock1, J M S Allison, W M Elshamy.   

Abstract

Cells' ability to evade cell death and to proliferate post geno-/cell-toxic stresses likely leads to formation of cancer. Activation of p38MAPK and p53 following these stresses helps protect cells against cancer development by initiating apoptosis. The duration of p38MAPK and p53 activation is regulated by the WIP1 phosphatase. BRCA1-IRIS triggers WIP1 expression in a p53-dependent and -independent manner. BRCA1-IRIS triggers the expression and cytoplasmic localization of the mRNA stabilization and translation inducer, HuR, that binds p53 and PPM1D mRNA. Hence, BRCA1-IRIS overexpression inactivates p38MAPK and/or p53 by upregulating WIP1 expression. BRCA1-IRIS abrogation of the homeostatic balance maintained by the p38MAPK-p53-WIP1 pathway suppressed cell death induced by a lethal dose of short-wavelength UV light, and high dosage of etoposide or H(2)O(2), and allowed cells to survive and proliferate post geno-/cell-toxic stresses. This mechanism represents a new link between geno-/cell-toxic stress and aggressive breast cancer formation in p53 wild-type cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20622893     DOI: 10.1038/onc.2010.262

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin.

Authors:  B T Paul; Z Blanchard; M Ridgway; W M ElShamy
Journal:  Oncogene       Date:  2014-08-18       Impact factor: 9.867

Review 2.  BRCA1-No Matter How You Splice It.

Authors:  Dan Li; Lisa M Harlan-Williams; Easwari Kumaraswamy; Roy A Jensen
Journal:  Cancer Res       Date:  2019-04-16       Impact factor: 12.701

3.  Novel insights linking BRCA1-IRIS role in mammary gland development to formation of aggressive PABCs: the case for longer breastfeeding.

Authors:  Patricia Castillo; Omonigho Aisagbonhi; Cheryl C Saenz; Wael M ElShamy
Journal:  Am J Cancer Res       Date:  2022-01-15       Impact factor: 6.166

Review 4.  Regulation of the Wip1 phosphatase and its effects on the stress response.

Authors:  Julie Lowe; Hyukjin Cha; Mi-Ok Lee; Sharlyn J Mazur; Ettore Appella; Albert J Fornace
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01

5.  BRCA1-IRIS overexpression promotes formation of aggressive breast cancers.

Authors:  Yoshiko Shimizu; Hugh Luk; David Horio; Penelope Miron; Michael Griswold; Dirk Iglehart; Brenda Hernandez; Jeffrey Killeen; Wael M ElShamy
Journal:  PLoS One       Date:  2012-04-12       Impact factor: 3.240

6.  BRCA1/p220 loss triggers BRCA1-IRIS overexpression via mRNA stabilization in breast cancer cells.

Authors:  Yoshiko Shimizu; Nicole Mullins; Zannel Blanchard; Wael M Elshamy
Journal:  Oncotarget       Date:  2012-03

7.  The role of PPM1D in cancer and advances in studies of its inhibitors.

Authors:  Wenhong Deng; Jieqing Li; Kimberly Dorrah; Denise Jimenez-Tapia; Brando Arriaga; Qiongyu Hao; Wei Cao; Zhaoxia Gao; Jay Vadgama; Yong Wu
Journal:  Biomed Pharmacother       Date:  2020-01-29       Impact factor: 7.419

8.  BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.

Authors:  Zannel Blanchard; Bibbin T Paul; Barbara Craft; Wael M ElShamy
Journal:  Breast Cancer Res       Date:  2015-01-13       Impact factor: 6.466

Review 9.  Current Evidence and Future Perspectives on HuR and Breast Cancer Development, Prognosis, and Treatment.

Authors:  Ioly Kotta-Loizou; Spyridon N Vasilopoulos; Robert H A Coutts; Stamatios Theocharis
Journal:  Neoplasia       Date:  2016-10-18       Impact factor: 5.715

10.  Premature polyadenylation of MAGI3 is associated with diminished N6-methyladenosine in its large internal exon.

Authors:  Thomas K Ni; Jessica S Elman; Dexter X Jin; Piyush B Gupta; Charlotte Kuperwasser
Journal:  Sci Rep       Date:  2018-01-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.